Recent Business Results

Performance (consolidated)

(¥ billion)

  2007 2008 2009 2010 2011
Net Sales 59.5 63.1 62.9 63.5 67.3
Recurring Profit 6.9 8.0 6.8 5.5 6.2
Net Income 4.0 4.5 4.1 4.0 3.7

Leading Products

May 2012
(¥ billion)

Brand name Active Ingredient Indications Launch
Date
Sales
2010
Sales
2011
Sales 2012
(estimated)
Apr.-Sep. Annual
Eviprostat herbal
extracts
prostatic
hypertrophy
Apr-67 6.3 5.9 2.7 5.2
Gaslon N irsogladine
maleate
gastric ulcer,
gastritis
Apr-89 4.5 4.9 2.4 4.9
Vidaza azacitidine myelodysplastic
syndrome
Mar-11 0.3 4.6 3.2 7.0
Hypen etodolac inflammation
(NSAIDs)
Sep-94 4.8 4.4 1.9 3.6
Lunabell norethisterone
and ethinylestradiol
dysmenorrhea Jul-08 3.1 3.8 2.1 4.3
Cialis tadalafil erectile
dysfunction
Jul-09 2.7 3.0 1.6 3.3
Cephadol difenidol
hydrochloride
vertigo Apr-74 2.7 2.6 1.2 2.4
Azunol
Gargle
sodium
gualenate
pharyngitis,
tonsillitis,
stomatitis,etc.
Aug-02 2.5 2.6 1.2 2.5
Bladderon flavoxate
hydrochloride
pollakiuria Apr-79 2.8 2.5 1.1 2.1
Selectol celiprolol
hydrochloride
hypertension,
angina pectoris
Sep-92 2.9 2.5 1.1 2.1
Estracyt estramustine
phosphate
prostatic
cancer
Apr-84 2.6 2.4 1.1 2.1
Cylocide cytarabine solid tumor,
acute leukemia
Apr-71 2.7 2.3 1.2 2.3
Baynas ramatroban allergic
rhinitis
Jul-06 2.6 2.2 0.8 2.3
Livostin levocabastine
hydrochloride
allergic rhinitis
and conjunctivitis
Jan-00 1.9 1.3 0.3 1.5
Adcirca tadalafil pulmonary arterial
hypertension
Dec-09 0.5 1.1 0.8 1.8
Erizas dexamethasone
cipecilate
allergic rhinitis Dec-09 0.5 0.7 0.5 2.0
NIPPON SHINYAKU Home Page